Literature DB >> 9456240

A high-risk lesion for invasive breast cancer, ductal carcinoma in situ, exhibits frequent overexpression of retinoid X receptor.

J A Lawrence1, M J Merino, J F Simpson, R E Manrow, D L Page, P S Steeg.   

Abstract

The development of prevention strategies for breast cancer will require a molecular map of carcinogenesis. We have investigated gene expression patterns in premalignant and early carcinomatous human breast lesions that confer to the patient varying risks for developing invasive breast cancer. The relative expression levels of one of the retinoid receptors, retinoid X receptor (RXR), was determined by in situ hybridization to 58 biopsy specimens; RXR mRNA grain density over each lesion was compared to that over the normal ductal/lobular units in each section. Overexpression of RXR mRNA was observed in 66% of noncomedo ductal carcinoma in situ (DCIS), which confer a >8-fold increase in breast cancer risk, and 88% of comedo DCIS lesions, which are associated with a yet higher risk. In contrast, only 8% of lesions that confer little or no increase in breast cancer risk overexpressed RXR mRNA (P = 0.0008). Limited in situ hybridization data using retinoic acid receptor (RAR) riboprobes showed overexpression of RAR alpha, but not RAR beta or -gamma, in only a modest percentage (36%) of cases, suggesting that all members of the retinoid receptor superfamily are not similarly regulated. Immunohistochemistry performed on 52 DCIS specimens for alpha, beta, and gamma isoforms of RXR confirmed its overexpression at the protein level and implicate RXR alpha as the predominant overexpressed form. The data indicate that RXR overexpression is associated with an increased risk for the development of invasive breast cancer in human breast lesions and suggest the hypothesis that it is causally involved in breast oncogenesis. The implications for retinoid chemoprevention are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9456240

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  13 in total

1.  Therapeutic Implications of PPARgamma in Human Osteosarcoma.

Authors:  Eric R Wagner; Bai-Cheng He; Liang Chen; Guo-Wei Zuo; Wenli Zhang; Qiong Shi; Qing Luo; Xiaoji Luo; Bo Liu; Jinyong Luo; Farbod Rastegar; Connie J He; Yawen Hu; Barrett Boody; Hue H Luu; Tong-Chuan He; Zhong-Liang Deng; Rex C Haydon
Journal:  PPAR Res       Date:  2010-02-16       Impact factor: 4.964

2.  Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients.

Authors:  J Jack Lee; Xifeng Wu; Michelle A T Hildebrandt; Hushan Yang; Fadlo R Khuri; Edward Kim; Jian Gu; Yuanqing Ye; Reuben Lotan; Margaret R Spitz; Waun Ki Hong
Journal:  Cancer Prev Res (Phila)       Date:  2011-02

3.  Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers.

Authors:  Shelley A Gestl; Mitchell D Green; Debra A Shearer; Elizabeth Frauenhoffer; Thomas R Tephly; Judith Weisz
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

4.  Altered localization of retinoid X receptor alpha coincides with loss of retinoid responsiveness in human breast cancer MDA-MB-231 cells.

Authors:  T Tanaka; B L Dancheck; L C Trifiletti; R E Birnkrant; B J Taylor; S H Garfield; U Thorgeirsson; L M De Luca
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

5.  Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk.

Authors:  Sara Karami; Paul Brennan; Philip S Rosenberg; Marie Navratilova; Dana Mates; David Zaridze; Vladimir Janout; Helena Kollarova; Vladimir Bencko; Vsevolod Matveev; Neonila Szeszenia-Dabrowska; Ivana Holcatova; Meredith Yeager; Stephen Chanock; Idan Menashe; Nathaniel Rothman; Wong-Ho Chow; Paolo Boffetta; Lee E Moore
Journal:  PLoS One       Date:  2009-09-15       Impact factor: 3.240

6.  Role of retinoid X receptor mRNA expression in Barrett's esophagus.

Authors:  Jan Brabender; Reginald V Lord; Ralf Metzger; JiMin Park; Dennis Salonga; Kathleen D Danenberg; Arnulf H Hölscher; Peter V Danenberg; Paul M Schneider
Journal:  J Gastrointest Surg       Date:  2004 May-Jun       Impact factor: 3.452

7.  Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid.

Authors:  Wen Jiang; Wentao Deng; Sarah K Bailey; Clint D Nail; Andra R Frost; Wayne J Brouillette; Donald D Muccio; Clinton J Grubbs; J Michael Ruppert; Susan M Lobo-Ruppert
Journal:  Cancer Biol Ther       Date:  2009-02-21       Impact factor: 4.742

8.  Function annotation of hepatic retinoid x receptor α based on genome-wide DNA binding and transcriptome profiling.

Authors:  Qi Zhan; Yaping Fang; Yuqi He; Hui-Xin Liu; Jianwen Fang; Yu-Jui Yvonne Wan
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

9.  A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands.

Authors:  David L Crowe; Roshantha A S Chandraratna
Journal:  Breast Cancer Res       Date:  2004-07-23       Impact factor: 6.466

10.  Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha.

Authors:  Isabel Conde; María V T Lobo; Javier Zamora; Julio Pérez; Francisco J González; Emilio Alba; Benito Fraile; Ricardo Paniagua; María I Arenas
Journal:  BMC Cancer       Date:  2008-06-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.